Simeon George Discloses Investment at Odyssey Therapeutics with 8.0% Stake

Simeon George, M.D., who leads SR One Capital Management, disclosed an 8.0% stake in Odyssey Therapeutics, Inc. through affiliated SR One funds. The position follows Odyssey’s IPO that closed on May 11, 2026, and the Schedule 13D filed on May 18, 2026. The stake combines IPO purchases with conversions of preferred stock and warrant exercises held by several SR One vehicles.Investor IntentSR One states that it holds Odyssey shares for investment. "The Funds acquired their respective shares for investment purposes." The group does not outline plans for board changes, mergers, asset sales, or other corporate actions at this time.The funds signed a 180-day IPO lock-up starting May 7, 2026, restricting sales, hedging, and new registration demands. They also hold demand, shelf, and piggyback registration rights that allow future sales once windows open, with the company covering registration costs. "Each Fund entered into a lock-up agreement ... for a period of 180 days after May 7, 2026."Investor's BackgroundSimeon George, M.D., is the managing member of SR One Capital Management, a Delaware-based life sciences investment firm. SR One focuses on early and growth-stage biotech companies, backing drug discovery and development across therapeutic areas. The firm, formed from the venture heritage associated with GlaxoSmithKline, has led and co-led numerous biotech financings and IPOs.Original SEC Filing: Odyssey Therapeutics, Inc. [ ODTX ] - SCHEDULE 13D - May. 18, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.